On March 31, 2026, the U.S. District Court for the District of Columbia vacated a 2013 Health Resources and Services Administration (HRSA) policy regarding a 2013 policy. Historically, disproportionate share hospitals (DSH) were barred from using a Group Purchasing Organization (GPO) to buy outpatient drugs if they also participated in the 340B program. HRSA’s 2013 policy extended this to include a hospital’s initial drug purchases even before those drugs were designated for a specific patient.
The Ruling: The court found this policy unlawful and “arbitrary and capricious.” It ruled that HRSA overstepped its authority by adding restrictions that Congress did not explicitly include in the law.
The Caveat: The court sent the issue back to HRSA. While HRSA could try to implement a similar rule again, it must now follow a much stricter administrative process (the Administrative Procedures Act) and prove it has the legal authority to do so instead of the ruling being completely struck down. According to legal analyses from Latham & Watkins and King & Spalding, this decision has several immediate and long-term implications for senior leadership:
Greater Purchasing Flexibility: Hospitals may now have more leeway to use GPOs for initial drug inventory. Previously, the “GPO Prohibition” forced hospitals into a “replenishment” model where they had to buy drugs at a higher price first and then “claim” 340B savings later. This ruling could simplify the “split-billing” software logic that hospitals use to track every pill, potentially reducing administrative overhead.
Financial Relief for “Child Sites:” This ruling is being viewed in tandem with a March 3, 2026, decision (Albany Med Health System v. HRSA) where the court also struck down registration requirements for off-campus “child sites.” Hospitals can now access 340B pricing for new outpatient clinics almost immediately, rather than waiting up to 23 months for the site to appear on a Medicare cost report and HRSA’s database. For health systems expanding their outpatient footprints, this removes a significant financial “lag” in realizing drug discounts.
This ruling could also mark a shift where HRSA’s “guidance” is no longer treated as law. For a CEO, this means legal and pharmacy compliance teams have more ground to challenge HRSA audits that rely on “substantive conditions” not found in the original 1992 statute. Complying with the 2013 HRSA policy cost individual hospitals between $500,000 and $1.6 million annually with 90% of DSH hospitals reported that this policy artificially inflated their spending in non-340B accounts.
This ruling is a supply chain efficiency win. It removes a decade-old administrative hurdle that forced hospitals to buy drugs at higher prices upfront. In an era of thin margins and high drug costs, this restores a level of purchasing power to GPOs like Premier and the health systems they serve.